Key facts
- Baebies’s last known valuation is $38.0M (Jul 2015).
- It has raised $51.6M across 5 recorded rounds; the latest was Seed Round ($2.0M) in Sep 2025.
- Notable investors include National Institutes of Health, IAG Capital Partners, Duke Capital Partners, Illumina Ventures, CARB-X — 42 tracked in total.
- Baebies has filed 7 Form Ds with the SEC since 2015, most recently Sep 2025 ($2.0M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 42 names
- ·Watchlist + deal alerts for Baebies
Funding rounds
5 roundsAbout Baebies
Provider of a screening and pediatric testing technology intended to save the lives of newborns. The company's technology operates on digital microfluidics, which maximizes diagnostic yield from low-volume samples, and one drop of blood is used to quantitatively measure the activity of lysosomal enzymes from newborn dried blood spot specimens, enabling patients with early disease detection and multifunctional diagnostics for syndromic testing for children and adults.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Employees
- 71
- Website
- baebies.com/
- Ownership
- Privately Held (backing)
Baebies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baebies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baebies in its N-PORT filings yet. We sweep new filings monthly.